ArticleNature medicine2016
Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Nature medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 160 papers.
0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed
14.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 203 citations in OpenAlex.
- Trial
- Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.The Journal of infectious diseases · 2022Trial
- Th2-Biased Transcriptional Profile Predicts HIV Envelope-Specific Polyfunctional CD4Journal of immunology (Baltimore, Md. : 1950) · 2022Trial
- A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination.Cell reports. Medicine · 2021Trial
- Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge.PLoS pathogens · 2020Trial
- Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.The lancet. HIV · 2018Trial
- HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine.Journal of virology · 2018Trial
- Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.The Journal of infectious diseases · 2017Trial
- Preferential engagement of the anti-inflammatory ATP/adenosine axis by HIV vaccine candidate with V1-deleted envelope in male rhesus macaques.Cell reports. Medicine · 2026Article
- Sustained mucosal delivery of SAMT-247 via an intravaginal ring reduces the risk of SIVCell reports. Medicine · 2026Article
- Mass spectrometry-based de novo sequencing reveals non-canonical neoantigens with antitumor efficacy in hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2026Article
- Friend or foe: divergent immunomodulatory effects of metabolites derived from the virucidal zinc finger inhibitor SAMT-247.Frontiers in immunology · 2026Article
- IgG and Fc Receptor Genetic Variation Associates With Functional Antibody Responses in a DNA and Protein Candidate HIV Vaccine Trial.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Losing Less in Translation: Relating the Preclinical Evidence Base for Active and Passive Immunity to Prevention of HIV-1 Infection in Humans.Journal of medical primatology · 2025Review
- Effects and mechanisms of monoclonal and polyclonal human antibodies in protection of humanized mice from HIV-1 challenge.bioRxiv : the preprint server for biology · 2025Article
- N-Glycosylation of Antibodies: Biological Effects During Infections and Therapeutic Applications.Antibodies (Basel, Switzerland) · 2025Review
- HIV vaccine candidate ΔV1gp120 formulated in ALFQA adjuvant augments mucosal immunity in female macaques.Nature communications · 2025Article
- Online Conference "Chronic Viral Infections and Cancer, Openings for Vaccines and Cure" VIRCAN2024, Monitoring the Progress.Vaccines · 2025Article
- BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.JCI insight · 2025Article
- N-glycosylation patterns of plasma immunoglobulin G in anti-synthetase syndrome disease.Frontiers in immunology · 2025Article
100 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
53 authors at 16 institutions in 4 countries.
Monica VaccariAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Shari N GordonAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Slim FouratiDepartment of Pathology, Case Western Reserve, Cleveland, Ohio, USA.
Luca SchifanellaAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Namal P M LiyanageAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Mark CameronDepartment of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland, USA.
Xiaoying ShenDuke Human Vaccine Institute, Durham, North Carolina, USA.
Georgia D TomarasDuke Human Vaccine Institute, Durham, North Carolina, USA.
Erik BillingsUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Mangala RaoUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Amy W ChungRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA.
Karen G DowellDepartment of Computer Science, Dartmouth College, Hanover, New Hampshire, USA.
Chris Bailey-KelloggDepartment of Computer Science, Dartmouth College, Hanover, New Hampshire, USA.
Eric P BrownThayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA.
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA.
Diego A Vargas-InchausteguiImmune Biology of Retroviral Infection Section, National Cancer Institute, Bethesda, Maryland, USA.
Stephen WhitneyAdvanced Bioscience Laboratories, Rockville, Maryland, USA.
Melvin N DosterAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Nicolo BinelloAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Poonam PeguAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
David C MontefioriDuke University Medical Center, Durham, North Carolina, USA.
Kathryn FouldsVaccine Research Center, US National Institutes of Health, Bethesda, Maryland, USA.
David S QuinnVaccine Research Center, US National Institutes of Health, Bethesda, Maryland, USA.
Mitzi DonaldsonVaccine Research Center, US National Institutes of Health, Bethesda, Maryland, USA.
Frank LiangKarolinska Institute, Stockholm, Sweden.
Karin LoréKarolinska Institute, Stockholm, Sweden.
Mario RoedererVaccine Research Center, US National Institutes of Health, Bethesda, Maryland, USA.
Richard A KoupVaccine Research Center, US National Institutes of Health, Bethesda, Maryland, USA.
Adrian McDermottVaccine Research Center, US National Institutes of Health, Bethesda, Maryland, USA.
Zhong-Min MaCalifornia National Primate Research Center, University of California, Davis, California, USA.
Christopher J MillerCalifornia National Primate Research Center, University of California, Davis, California, USA.
Tran B PhanUniversity of California, Irvine School of Medicine, Irvine, California, USA.
Donald N ForthalUniversity of California, Irvine School of Medicine, Irvine, California, USA.
Matthew BlackburnAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Francesca CaccuriAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Massimiliano BissaAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
Guido FerrariDuke Human Vaccine Institute, Durham, North Carolina, USA.
Vaniambadi KalyanaramanAdvanced Bioscience Laboratories, Rockville, Maryland, USA.
Maria G FerrariAdvanced Bioscience Laboratories, Rockville, Maryland, USA.
DeVon ThompsonAdvanced Bioscience Laboratories, Rockville, Maryland, USA.
Marjorie Robert-GuroffImmune Biology of Retroviral Infection Section, National Cancer Institute, Bethesda, Maryland, USA.
Silvia Ratto-KimUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Jerome H KimUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Nelson L MichaelUS Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Sanjay PhogatSanofi Pasteur, Swiftwater, Pennsylvania, USA.
Susan W BarnettNovartis Vaccines and Diagnostics, Inc., Cambridge, USA.
Jim TartagliaSanofi Pasteur, Swiftwater, Pennsylvania, USA.
David VenzonBiostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-8990-158X
Donald M StableinThe EMMES Corporation, Rockville, Maryland, USA.
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, Massachusetts, USA.
Rafick-Pierre SekalyDepartment of Pathology, Case Western Reserve, Cleveland, Ohio, USA.
Genoveffa FranchiniAnimal Models and Vaccine Section, National Cancer Institute, Bethesda, Maryland, USA.
National Cancer Institute · USNational Institutes of Health · USAdvanced Bioscience Laboratories (United States) · USDartmouth College · USWalter Reed Army Institute of Research · USCase Western Reserve University · USInternational Vaccine Institute · KRKarolinska Institutet · SERagon Institute of MGH, MIT and Harvard · USSanofi (United States) · USUniversity of California, Davis · USUniversity of California, Irvine · USDuke Medical Center · USEmmes (United States) · USLeidos (United States) · USUniversity of Milan · IT
Funding
Preventive Vaccines for HIVZIABC011126 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI FRANCHINI, GENOVEFFA · 2009 to 2025
$55.3MSocial and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI GEORGIA Doris TOMARAS · 2005 to 2026
$50.5MNon-Human Primate CoreZICAI005103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2009 to 2025
$22.7MThe role of antibody and the Fc neonatal receptor in transmitted/founder strain selectionR01AI118581 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N · 2015 to 2019
$2.9MThe impact of antibody and pH on female-to-male SIV infectionR01AI102715 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FORTHAL, DONALD N, MILLER, CHRISTOPHER JAMES · 2012 to 2015
$2.7MApplying High-Performance Protein Engineering Tools to HIV Immunogen DesignR01AI102691 · NIAID · DARTMOUTH COLLEGE · PI ACKERMAN, MARGARET E · 2012 to 2015
$2.2MIntramural NIH HHS Z99 CA999999NIAID NIH HHS HHSN266200700005CNIAID NIH HHS HHSN272201100016CNIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI102691NIAID NIH HHS R01 AI102715NIAID NIH HHS R01 AI118581
Abstract
A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)-HIV and gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution of alum with the more immunogenic MF59 adjuvant is under consideration for the next efficacy human trial. We found here that an ALVAC-simian immunodeficiency virus (SIV) and gp120 alum (ALVAC-SIV + gp120) equivalent vaccine, but not an ALVAC-SIV + gp120 MF59 vaccine, was efficacious in delaying the onset of SIVmac251 in rhesus macaques, despite the higher immunogenicity of the latter adjuvant. Vaccine efficacy was associated with alum-induced, but not with MF59-induced, envelope (Env)-dependent mucosal innate lymphoid cells (ILCs) that produce interleukin (IL)-17, as well as with mucosal IgG to the gp120 variable region 2 (V2) and the expression of 12 genes, ten of which are part of the RAS pathway. The association between RAS activation and vaccine efficacy was also observed in an independent efficacious SIV-vaccine approach. Whether RAS activation, mucosal ILCs and antibodies to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.
Indexed as
Adaptive ImmunityAdjuvants, ImmunologicAlum CompoundsAnimalsImmunity, InnateImmunity, MucosalImmunogenicity, VaccineImmunoglobulin GInterleukin-17LymphocytesMacaca mulattaMembrane GlycoproteinsRandom Allocationras ProteinsSAIDS VaccinesSignal TransductionAdjuvants, ImmunologicAlum Compoundsaluminum sulfateALVAC vaccinegp120 protein, Simian immunodeficiency virusImmunoglobulin GInterleukin-17Membrane Glycoproteinsras ProteinsSAIDS VaccinesViral Envelope ProteinsViral Vaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.